125 related articles for article (PubMed ID: 8422593)
1. Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
Stoot J; Wils J; von Geuns H; Smeets J; Schouten L
Cancer Invest; 1993; 11(1):1-5. PubMed ID: 8422593
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
Wils J; van Geuns H; Stoot J; Bergmans M; Boschma F; Bron H; Degen J; Erdkamp F; van Erp J; Haest J; Iding R; Lalisang F; de Pree N; de Rooy C; Snijders M; Schepers J; Vreeswijk J; Wals J; Werter M; Wetzels L; Smeets J; Schouten L
Anticancer Drugs; 1999 Mar; 10(3):257-61. PubMed ID: 10327029
[TBL] [Abstract][Full Text] [Related]
3. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
[TBL] [Abstract][Full Text] [Related]
5. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
[TBL] [Abstract][Full Text] [Related]
6. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1873-5. PubMed ID: 2697191
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Wils JA
Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
Hernádi Z; Juhász B; Póka R; Lampé LG
Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
[TBL] [Abstract][Full Text] [Related]
15. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
[TBL] [Abstract][Full Text] [Related]
16. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
[TBL] [Abstract][Full Text] [Related]
17. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
[TBL] [Abstract][Full Text] [Related]
18. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
20. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.
Alberts DS; Dahlberg S; Green SJ; Garcia D; Hannigan EV; O'Toole R; Stock-Novack D; Surwit EA; Malviya VK; Jolles CJ
Cancer; 1993 Jan; 71(2 Suppl):618-27. PubMed ID: 8420685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
